Treatment of bone loss in oophorectomized women with a combination of ipriflavone and conjugated equine estrogen

@article{Nozaki1998TreatmentOB,
  title={Treatment of bone loss in oophorectomized women with a combination of ipriflavone and conjugated equine estrogen},
  author={M. Nozaki and Kazunori Hashimoto and Yoji Inoue and R Ogata and A Okuma and Hitoshi Nakano},
  journal={International Journal of Gynecology \& Obstetrics},
  year={1998},
  volume={62}
}
Objective: We previously reported that 0.625 mg/day of conjugated equine estrogen (CEE) could not prevent acute bone loss in the first year after oophorectomy. The effect of additional administration of ipriflavone on bone mineral density (BMD) and biochemical indices of bone remodeling were studied to investigate whether concurrent use of CEE and ipriflavone prevent acute bone loss in the early stages following surgical menopause. Methods: One‐hundred and sixteen oophorectomized women were… Expand
Effects of Ipriflavone on Bone Loss Following a Bilateral Ovariectomy and Menopause: A Randomized Placebo-Controlled Study
TLDR
The effect of IP alone on bone loss in the early stage is not sufficient to reduce the risk of osteoporosis in later life, and IP suppressed bone loss compared with placebo did not prevent acute bone loss following ovariectomy. Expand
The effect of bilateral oophorectomy on bone mineral density
TLDR
The bilateral oophorectomy as a surgical procedure is not a statistically significant factor for the acceleration of the bone loss if the surgery is performed before and after the menopause. Expand
Combination treatment of osteoporosis: a clinical review.
  • C. Crandall
  • Medicine
  • Journal of women's health & gender-based medicine
  • 2002
TLDR
The few trials including Food and Drug Administration (FDA)-approved medications suggest that 10 mg/day alendronate with estrogen can increase BMD moreso than each medication given singly in postmenopausal osteoporotic women. Expand
Dietary l-carnitine supplementation improves bone mineral density by suppressing bone turnover in aged ovariectomized rats.
TLDR
It is suggested that carnitine supplementation slows bone loss and improves bone microstructural properties by decreasing bone turnover. Expand
Ipriflavone: an important bone-building isoflavone.
  • K. Head
  • Medicine
  • Alternative medicine review : a journal of clinical therapeutic
  • 1999
TLDR
While ipriflavone appears to enhance estrogen's effect, it does not possess intrinsic estrogenic activity, making it an attractive adjunct or alternative to conventional hormone replacement therapy. Expand
Bone Mineral Density Thresholds for Pharmacological Intervention to Prevent Fractures
TLDR
A strategy to reduce overall fracture incidence will likely require lifestyle changes and a targeted effort to identify and develop treatment protocols for women with less severe low bone mass who are nonetheless at increased risk for future fractures. Expand
Bone mineral density thresholds for pharmacological intervention to prevent fractures.
TLDR
A strategy to reduce overall fracture incidence will likely require lifestyle changes and a targeted effort to identify and develop treatment protocols for women with less severe low bone mass who are nonetheless at increased risk for future fractures. Expand
Efficacy of a soy rich diet in preventing postmenopausal osteoporosis: the Menfis randomized trial.
TLDR
The data suggest that soy products could be effective in reducing the risk of osteoporosis in asymptomatic postmenopausal women, but the findings should be confirmed before recommending the diet as a valid alternative to HRT. Expand
Icariin Flavonoid in Horny Goat Weed Boosts Bone Density in Postmenopausal Women
The incidence of osteoporosis in North America is estimated to affect one in four women and one in four men over the age of 50, with complications from osteoporotic fractures accounting for moreExpand
Soy protein isolate with isoflavones does not prevent estradiol-induced endometrial hyperplasia in postmenopausal women: a pilot trial
TLDR
In this pilot study, SPI with isoflavones did not protect the endometrium from E2-induced hyperplasia in postmenopausal women, and future studies combining E2 with is oflavones may be feasible as an alternative to traditional hormone replacement therapy. Expand
...
1
2
...

References

SHOWING 1-10 OF 19 REFERENCES
Differential time‐related effects of conjugated equine estrogen on bone metabolism in oophorectomized women
TLDR
In the initial 2‐year period after oophorectomy, 0.625 mg/day of CEE alone could not prevent acute bone loss suggesting that additional therapy for the prevention of osteoporosis may be needed. Expand
Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: a 2-year prospective study.
TLDR
Continuous hormone replacement therapy (HRT) using 0.31 mg of CEE and 2.5 mg of MPA is effective in increasing lumbar BMD in postmenopausal or oophorectomized women and can be an appropriate option for women with a normal lipid profile or those women wishing to eliminate unscheduled bleeding. Expand
Ipriflavone Prevents Bone Loss in Postmenopausal Women
TLDR
Ipriflavone may represent a useful aid for the prevention of BMD decline in postmenopausal women because of its ability to regulate bone metabolism and endocrine parameters. Expand
The chronological change of vertebral bone loss following oophorectomy using dual energy X-ray absorptiometry: the correlation with specific markers of bone metabolism.
TLDR
The maximal bone loss in the first year is considered to be caused by the remarkable increase of bone resorption and the biological delay of the maximal increase in bone formation. Expand
[Usefulness of estriol for the treatment of bone loss in postmenopausal women].
TLDR
Data indicate that the acceleration of bone turnover usually observed after menopause was prevented by treatment with estriol, and reasonable compliance can be expected among postmenopausal women treated with E3 to prevent bone loss. Expand
[Changes in bone mineral density and bone turnover within 12 months after oophorectomy: a prospective study compared with hysterectomized controls].
TLDR
The data suggest that a rapid and considerable loss of spinal BMD was mainly accelerated by the oophorectomy, but in part was contributed to by the stress or reduced physical activity for up to 6 months after radical hysterectomy. Expand
Urinary excretion of pyridinium crosslinks of collagen in oophorectomized women as markers for bone resorption.
TLDR
The present study indicates that an increase of bone resorption which was evaluated by urinary HP and LP occurs in the early stage after oophorectomy, and it may, therefore, be good to begin estrogen replacement therapy as soon as possible after oophilectomy. Expand
Bone loss and biochemical indices of bone remodeling in surgically induced postmenopausal women.
TLDR
The maximal rate of bone loss, as judged by radiogrammetry of the metacarpals and by dual-photon absorptiometry of the lumbar spine, coincided with the peak of the dissociation between urinary hydroxyproline excretion and/or plasma tartrate resistant acid phosphatase activity, indicating continuous imbalance of bone remodeling in the patients. Expand
The Minimum Effective Dose of Estrogen for Prevention of Postmenopausal Bone Loss
In a controlled single blind study to determine the minimal effective dose of estrogen for protection against bone loss, conjugated equine estrogens in doses of 0.625 and 1.25 mg per day were equallyExpand
BONE MASS IN POSTMENOPAUSAL WOMEN AFTER WITHDRAWAL OF OESTROGEN/GESTAGEN REPLACEMENT THERAPY
TLDR
It is indicated that even temporary hormone replacement therapy after the menopause will have a lasting beneficial effect on bone mass. Expand
...
1
2
...